Established · publishing since 1979
Acute Myeloid Leukemia ResearchRNA Research and SplicingAcute Lymphoblastic Leukemia researchRNA modifications and cancerChronic Myeloid Leukemia Treatments
Publications
33
Citations
323
Est. group size
—
Recurring co-author estimate
Active years
48
Publishing since 1979
In context
Among 4,953 established Medicine PIs within our index
Citations: 323p25 789 · p75 7,423 · cohort median 2,544
Publications / year (recent): 3.6p25 2 · p75 10.6 · cohort median 4.8
Typically publishes in teams of ~12 · 7% small-team papers (≤3 authors) · across 16 venues
Publication cadence
Publications per year over the last 10 years — averaging 3.6/year recently
Collaborators per year
Distinct co-authors at University of Michigan each year — a rough indication of whether the group around this researcher has been growing or contracting. An estimate from co-authorship, not a roster: collaborators are not necessarily lab members, and recent years can be under-counted while indexing catches up.
Recent publications
- The tumor suppressor HNRNPK induces p53-dependent nucleolar stress to drive ribosomopathies
Journal of Clinical Investigation · 2025
- Hnrnpk haploinsufficiency in del(9q) Acute Myeloid Leukemia reveals targetable vulnerabilities
Blood · 2025
- Tfeb regulates CD8+ T-cell proliferation In Vivo
Blood · 2025
- The nucleolar aberrancies that drive ribosome impairment induced by RNA binding proteins are hallmarks of aging
bioRxiv (Cold Spring Harbor Laboratory) · 2023
- Figure S1. Notch-induced cell death in B-ALL. from Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia
2023
- Figure S2. CyTOF-SPADE analysis shows upregulation of p53 and Bax proteins by treatment with PLK1 inhibitor volasertib (BI6727) in primary B-ALL. from Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia
2023
- Figure S3. Differential expression of MDM2 and PARP1 in B-ALL patient samples. from Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia
2023
- Data from Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia
2023
- Figure S2. CyTOF-SPADE analysis shows upregulation of p53 and Bax proteins by treatment with PLK1 inhibitor volasertib (BI6727) in primary B-ALL. from Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia
2023
- Figure S3. Differential expression of MDM2 and PARP1 in B-ALL patient samples. from Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia
2023
- Figure S1. Notch-induced cell death in B-ALL. from Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia
2023
- Hnrnpk Overexpression Drives Nucleolar Aberrancies Causing Ribosomopathies
Blood · 2023
- Data from Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia
2023
- Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy
Antioxidants · 2022
- Heterogeneous nuclear ribonucleoprotein K is overexpressed in acute myeloid leukemia and causes myeloproliferation in mice via altered <i>Runx1</i> splicing
NAR Cancer · 2022
Publishes in
- Blood×5
- HemaSphere×2
- bioRxiv (Cold Spring Harbor Laboratory)×2
- Journal of Hematology & Oncology×1
- Antioxidants×1
Similar researchers
By research-topic overlap
- Yosra Ben Youssef
Medicine · The Ohio State University
- C. D. Bloomfield
Medicine · The Ohio State University
- Jessica Kohlschmidt
Medicine · The Ohio State University
- Patrick W. Burke
Medicine · University of Michigan
- Lydia L. Benitez
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile